- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis
Author(s):
Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.
Video Player is loading.
Related Videos
Utility of Molecular Testing in Skin Cancer Risk Assessment
Limitations and Challenges in Skin Cancer Staging Systems
Mechanism of Action Differences Among IL-17 Inhibitors
The Role of IL-17 in Psoriasis Pathogenesis
Navigating the Boxed Warning for the JAK Inhibitor Class
Personalized Photoprotection Based on Patient Factors
Impact of Oxidative Stress on Skin Health and the Utility of Antioxidants
Laboratory Monitoring for JAK Inhibitors and Key Takeaways
Options for Eyebrow and Eyelash Regrowth in a 32-Year-Old Female With Alopecia Areata
Efficacy, Safety, and Role in Therapy of JAK Inhibitors for Atopic Dermatitis
Related Content
